Department of Mathematics and Statistics, The University of Haripur, Haripur, KP, Pakistan.
Department of Statistics, GCU, Lahore, Pakistan.
Sci Rep. 2024 Aug 23;14(1):19573. doi: 10.1038/s41598-024-70481-9.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition globally and the leading cause of liver-related death and morbidity. The goal of this study was to collect current data in order to calculate the pooled prevalence of NAFLD in Pakistan. We conducted a comprehensive literature search on four electronic databases until March 2024 to find studies on the prevalence of NAFLD in Pakistan. Pooled prevalence estimates of NAFLD were obtained using random-effects meta-analytic models. The chi-square test was used to account for study heterogeneity, whereas the I statistic was used to assess inconsistency. The data were stratified by the general population (average risk) and individuals with metabolic diseases (high risk). Two reviewers thoroughly and independently screened, reviewed, and assessed all studies. In total, 468 studies were reviewed, and 34 were included. The pooled NAFLD prevalence in the general population was 29.82% (95% CI 21.39-39.01%; prediction interval: 2.98-68.92%) based on 13 studies. In individuals with metabolic disorders, the prevalence of NAFLD in patients with diabetes, hypertension, and obesity, was 58.47% (95% CI 54.23-62.64%; prediction interval: 38.16-77.40%), 74.08% (95% CI 60.50-85.70%), and 47.43% (95% CI 30.49-64.66%), respectively. There was no evidence of publication bias, although a statistically significant level of heterogeneity was seen among the studies (I ranged from 57.5 to 98.69%). The findings of this study indicate a substantial prevalence of NAFLD in the population of Pakistan. The Pakistani government must formulate a comprehensive approach and plan aimed at augmenting awareness, control, prevention, and treatment of fatty liver disease.Prospero Registration no: CRD42022356607.
非酒精性脂肪性肝病 (NAFLD) 是全球最常见的慢性肝病，也是与肝脏相关的死亡和发病的主要原因。本研究的目的是收集当前数据，以计算巴基斯坦 NAFLD 的患病率。我们对四个电子数据库进行了全面的文献检索，检索时间截至 2024 年 3 月，以寻找关于巴基斯坦 NAFLD 患病率的研究。使用随机效应荟萃分析模型获得 NAFLD 的汇总患病率估计值。卡方检验用于解释研究异质性，而 I 统计量用于评估不一致性。数据按普通人群（平均风险）和代谢疾病患者（高风险）进行分层。两名审查员彻底、独立地筛选、审查和评估了所有研究。共审查了 468 项研究，其中 34 项被纳入。基于 13 项研究，普通人群中 NAFLD 的总体患病率为 29.82%（95%CI 21.39-39.01%；预测区间：2.98-68.92%）。在代谢紊乱患者中，糖尿病、高血压和肥胖患者中 NAFLD 的患病率分别为 58.47%（95%CI 54.23-62.64%；预测区间：38.16-77.40%）、74.08%（95%CI 60.50-85.70%）和 47.43%（95%CI 30.49-64.66%）。虽然研究之间存在统计学上显著的异质性（I 范围为 57.5%至 98.69%），但没有证据表明存在发表偏倚。本研究的结果表明，巴基斯坦人群中 NAFLD 的患病率相当高。巴基斯坦政府必须制定全面的方法和计划，旨在增强对脂肪肝疾病的认识、控制、预防和治疗。
Prosporo 注册号：CRD42022356607。
